Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Abstract Text:

Giovanni Del Poeta,Maria Ilaria Del Principe,Francesco Buccisano,Luca Maurillo,Giovanni Capelli,Fabrizio Luciano,Alessio Pio Perrotti,Massimo Degan,Adriano Venditti,Paolo de Fabritiis,Valter Gattei,Sergio Amadori,Giovanni Del Poeta,Maria Ilaria Del Principe,Francesco Buccisano,Luca Maurillo,Giovanni Capelli,Fabrizio Luciano,Alessio Pio Perrotti,Massimo Degan,Adriano Venditti,Paolo de Fabritiis,Valter Gattei,Sergio Amadori,Giovanni Del Poeta,Maria Ilaria Del Principe,Francesco Buccisano,Luca Maurillo,Giovanni Capelli,Fabrizio Luciano,Alessio Pio Perrotti,Massimo Degan,Adriano Venditti,Paolo de Fabritiis,Valter Gattei,Sergio Amadori,

BACKGROUND.: Rituximab in sequential combination with fludarabine (Flu) allowed patients with B-cell chronic lymphocytic leukemia (B-CLL) to achieve higher remission rates and longer response duration. Based on their recent experience in indolent non-Hodgkin lymphomas, in this study, the authors attempted to demonstrate whether consolidation/maintenance therapy with rituximab could prolong the response duration in this patient population. METHODS.: This Phase II study was based on a consolidation/maintenance therapy with rituximab for patients in complete remission (CR) or partial remission (PR) who were positive for minimal residual disease (MRD), as determined by flow cytometry. Seventy-five symptomatic, untreated patients with B-CLL received 6 monthly cycles of Flu (25 mg/m(2) for 5 days) followed by 4 weekly doses of rituximab (375 mg/m(2)). Then, 28 patients who were positive for MRD were consolidated with 4 monthly cycles of rituximab (375 mg/m(2)) followed by 12 monthly low doses of rituximab (150 mg/m(2)). RESULTS.: Based on National Cancer Institute criteria, 61 of 75 patients (81%) achieved a CR, 10 of 75 patients (13%) had a PR, and 4 of 75 patients (5%) had either no response or disease progression. MRD-positive patients in CR or PR who received consolidation therapy (n = 28 patients) had a significantly longer response duration (87% vs 32% at 5 years; P = .001) compared with a subset of patients who did not receive consolidation therapy (n = 18 patients). All patients experienced a long progression-free survival from the end of induction treatment (73% at 5 years). It was noteworthy that, within the subset of ZAP-70-positive patients, MRD-positive, consolidated patients (n = 12 patients) had a significantly longer response duration (69% vs 0% at 2.6 years; P = .007) compared with MRD-positive, unconsolidated patients (n = 11 patients). CONCLUSIONS.: The addition of a consolidation and maintenance therapy withrituximab prolonged response duration significantly in patients with MRD-positive B-CLL. Cancer 2008. (c) 2007 American Cancer Society.

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Publishing Authors By Initials

G Del Poeta,MI Del Principe,F Buccisano,L Maurillo,G Capelli,F Luciano,AP Perrotti,M Degan,A Venditti,P de Fabritiis,V Gattei,S Amadori,G Del Poeta,MI Del Principe,F Buccisano,L Maurillo,G Capelli,F Luciano,AP Perrotti,M Degan,A Venditti,P de Fabritiis,V Gattei,S Amadori,G Del Poeta,MI Del Principe,F Buccisano,L Maurillo,G Capelli,F Luciano,AP Perrotti,M Degan,A Venditti,P de Fabritiis,V Gattei,S Amadori,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cancer

VOLUME: 112

Page Numbers: 119-28

Journal Abbreviation: Cancer

ISSN: 0008-543X

DAY: 1

MONTH: Jan

YEAR: 2008

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 374236

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.

AFFILIATION: Department of Hematology, University "Tor Vergata," S. Eugenio Hospital, Rome, Italy.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia Related Publications

• A novel t(11;12)(q23-24;q24) in a case of minimally-differentiated acute myeloid leukemia (AML-M0).
• Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma.
• Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab.
• Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.
• Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia.
• Differential regulation of hypoxia-induced CXCR4 triggering during B-cell development and lymphomagenesis.
• FISH analysis of chromosomes 3 and 6 on fine needle aspiration biopsy samples identifies distinct subgroups of uveal melanomas.
• Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer.
• Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
• Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management.
• Inhibition of growth of breast cancer cells in vitro by the ribosome-inactivating protein saporin 6.
• Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia.
• Novel thrombopoietic agents : a review of their use in idiopathic thrombocytopenic purpura.
• Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study.
• Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies.
• Production and characterization of monoclonal antibodies differentiating subpopulations of porcine B lymphocytes in blood and lymphoid tissues.
• Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura.
• Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia.
• Saporin 6 and lonidamine in primary cell cultures from human breast carcinomas: a synergistic effect.
• The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects.